Search

Now showing items 1-7 of 7

Transforming growth factor-beta (TGF-β) in prostate cancer: A dual function mediator?

Mirzaei, S.; Paskeh, M.D.A.; Saghari, Y.; Zarrabi, A.; Hamblin, M.R.; Entezari, M.; Hashemi, M.; Aref, A.R.; Hushmandi, K.; Kumar, A.P.; Rabiee, N.; Ashrafizadeh, M. (Elsevier B.V., 2022)

Transforming growth factor-beta (TGF-β) is a member of a family of secreted cytokines with vital biological functions in cells. The abnormal expression of TGF-β signaling is a common finding in pathological conditions, ...

The association between albumin-globulin ratio (AGR) and survival in patients treated with immune checkpoint inhibitors

Guven, Deniz Can; Aktepe, Oktay Halit; Aksun, Melek Seren; Sahin , Taha Koray; Kavgaci, Gozde; Ucgul, Enes; Cakir, Ibrahim Yahya; Yildirim, Hasan Cagri; Guner, Gurkan; Akin, Serkan; Kertmen, Neyran; Dizdar, Omer; Aksoy, Sercan; Erman, Mustafa; Suayib, Yalcin; Kilickap, Saadettin (IOS Press, 2022)

BACKGROUND: The albumin-globulin ratio (AGR) could be a prognostic biomarker in patients with cancer, although the data is limited in patients treated with immune-checkpoint inhibitors (ICIs). OBJECTIVES: We aimed to ...

Atezolizumab combined with chemotherapy in the first-line treatment of extensive-stage small cell lung cancer: A real-life data of the Turkish Oncology Group

Gurbuz, Mustafa; Kutlu, Yasin; Akkus, Erman; Koksoy, Elif Berna; Kose, Naziyet; Oven, Bala Basak; Uluc, Basak Oyan; Demiray, Atike Gokcen; Erdem, Dilek; Demir, Bilgin; Turhal, Nazım Serdar; Uskent, Necdet; Akbas, Sinem; Selcukbiricik, Fatih; Inal, Ali; Bilici, Ahmet; Kilickap, Saadettin (Springer, 2022)

Purpose Atezolizumab has been shown to be efective and safe in randomized trial in the frst-line treatment of extensivestage small cell lung cancer (SCLC). However, there are limited real-life data on atezolizumab. In this ...

The Association between the Pan-Immune-Inflammation Value and Cancer Prognosis: A systematic review and meta-analysis

Guven, Deniz Can; Sahin, Taha Koray; Erul, Enes; Kilickap, Saadettin; Gambichler, Thilo; Aksoy, Sercan (PMC, 2022)

Background: Prognostic scores derived from the blood count have garnered significant interest as an indirect measure of the inflammatory pressure in cancer. The recently developed pan-immune-inflammation value (PIV), an ...

The relationship between pan-immune-inflammation value and survival outcomes in patients with metastatic renal cell carcinoma treated with nivolumab in the second line and beyond: A Turkish oncology group kidney cancer consortium (TKCC) study

Tural, Deniz; Yekeduz, Emre; Erturk, Ismail; Karakaya, Serdar; Erol, Cihan; Ercelep, Ozlem; Arslan, Cagatay; Sever, Ozlem Nuray; Senturk Oztas, Nihan; Kucukarda, Ahmet; Can, Orcun; Oksuzoglu, Berna; Sendur, Mehmet Ali; Karadurmus, Nuri; Urun, Yuksel; Kilickap, Saadettin (Springer, 2022)

Background Pan-immune-infammation value (PIV) is an easily accessible immune marker based on peripheral blood to estimate prognosis in patients with cancer. This study evaluates the prognostic value of PIV in patients ...

Differences between hyperprogressive disease and progressive disease in patients receiving immunotherapy

Yildirim, Hasan Cagri; Guven, Deniz Can; Aktepe, Oktay Halit; Taban, Hakan; Yilmaz, Feride; Yasar, Serkan; Aktas, Burak Yasin; Guner, Gurkan; Dizdar, Omer; Aksoy, Sercan; Erman, Mustafa; Yalcin, Suayib; Kilickap, Saadettin (Kare Publishing, 2022)

Objectives: Although immune checkpoint inhibitors (ICIs) became a vital part of cancer care, many patients do not respond to treatment. In this group, a few of the patients with a hyperprogressive disease (HPD) have shorter ...

Emerging role of exosomes in cancer progression and tumor microenvironment remodeling

Paskeh, Mahshid Deldar Abad; Entezari, Maliheh; Mirzaei, Sepideh; Zabolian, Amirhossein; Zarrabi, Ali (BioMed Central, 2022)

Cancer is one of the leading causes of death worldwide, and the factors responsible for its progression need to be elucidated. Exosomes are structures with an average size of 100 nm that can transport proteins, lipids, and ...